Agonist | hD2 | hD3 | EC50Ratio hD2/hD3 | ||||||
---|---|---|---|---|---|---|---|---|---|
pEC50 | EC50 | EMAX | nH | pEC50 | EC50 | EMAX | nH | ||
nM | % | nM | % | ||||||
Dopamine | 6.45 ± 0.03 | 350 | 103.5 ± 4.9 | 1.10 ± 0.10 | 8.00 ± 0.07 | 10 | 100.1 ± 3.2 | 0.82 ± 0.07 | 35 |
(+)-7-OH-DPAT | 7.35 ± 0.11 | 44.6 | 64.3 ± 2.8 | 0.86 ± 0.10 | 9.24 ± 0.26 | 0.58 | 55.4 ± 4.2 | 1.27 ± 0.24 | 77 |
PD 128,907 | 6.33 ± 0.10 | 467 | 116 ± 3.8 | 0.73 ± 0.18 | 8.91 ± 0.12 | 1.22 | 63.6 ± 2.8 | 1.21 ± 0.31 | 382 |
S 14297 | 7.31 ± 0.08 | 48.6 | 20.6 ± 1.9 | 1.53 ± 1.11 | n.c. | n.c. | 0 | n.c. | n.c. |
Agonist efficacies were determined by [35S]GTPγS binding. Results are means ± S.E. of mean of at least three independent experiments. EC50 values were calculated from mean pEC50 values. Haloperidol and GR 218,231 did not induce any alteration of [35S]GTPγS binding to either hD2 or hD3 membranes. S 14297 did not alter [35S]GTPγS binding to hD3 membranes.
n.c., not computable.